BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Dale Hooks has been named Senior Vice President and Chief Commercial Officer. Mr. Hooks succeeds Steve Hoerter, the Company’s current Chief Commercial Officer and Executive Vice President, who is leaving to pursue other opportunities. Hooks joined Clovis in 2014 and has served as a key member of the commercial leadership team involved in preparation for the potential launches of the Company’s late-stage investigational compounds, including rociletinib, for which a New Drug Application (NDA) is currently on file with the U.S. FDA, and rucaparib, for which an NDA is planned during the second quarter of 2016.
“I’m very pleased to announce Dale’s appointment as our Chief Commercial Officer,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Dale has been instrumental in building out our commercial organization, and he brings tremendous depth of experience in oncology sales and marketing to this role. As a company, we have the challenge and the opportunity to potentially launch two drugs within the next 12 months, and Dale has exactly the right skill set and background to lead this effort. I also want to express my great appreciation to Steve for all the contributions he has made to Clovis, and wish him the best going forward.”
Prior to his appointment as Chief Commercial Officer and Senior VP, Hooks served as Vice President of Sales at Clovis, where he has successfully established many of the Company’s key commercial capabilities, including the Field Sales, Commercial Training and Development and Data Management and Analytics functions. Prior to joining Clovis, Hooks spent nearly 10 years at Genentech, where he held a variety of marketing and sales leadership positions, most recently as Franchise Head, Sales & Marketing of the Skin Cancer franchise, where he was responsible for the development of a new oncology franchise focused on skin malignancies. During his tenure at Genentech, he was responsible for the commercialization and successful launches of several key oncology brands across a variety of solid tumor categories, including lung, breast, colorectal, pancreatic and gastric cancers. Prior to Genentech, Hooks served in a number of sales and marketing leadership roles at GSK, Novartis and Galderma.
As Chief Commercial Officer at Clovis, Hooks will be responsible for the global commercial efforts and will also serve on the Company’s executive committee. He will continue to be based in the Company’s San Francisco office.
Rociletinib is a novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as well as the dominant resistance mutation T790M. Data from both the pivotal, single-arm TIGER-X and TIGER-2 clinical trials served as the basis for the U.S. and EU regulatory submissions for the treatment of advanced mutant EGFR T790M-positive lung cancer. Rociletinib was given Breakthrough Therapy designation by the FDA in May 2014.
Rucaparib is an oral, potent inhibitor of PARP1 and PARP2 being developed for the treatment of advanced ovarian cancer in patients with BRCA mutations (genes that are linked to breast and ovarian cancers) and other DNA repair deficiencies. Data from three ongoing ovarian cancer clinical trials – ARIEL2, ARIEL2 extension, and Study 10 -- are expected to serve as the basis for the first U.S. regulatory submission for rucaparib, planned for the second quarter of 2016 for the treatment of BRCA-mutant advanced ovarian cancer. Rucaparib was given Breakthrough Therapy designation by the FDA in April 2015.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in our clinical development programs for our drug candidates, the corresponding development pathways of our companion diagnostics, actions by the FDA, the EMA or other regulatory authorities regarding whether to approve drug applications that may be filed, as well as their decisions regarding drug labeling, and other matters that could affect the availability or commercial potential of our drug candidates or companion diagnostics, including competitive developments. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.